Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons

Bryan D. Choi  MD PhD; William T. Curry  MD; Bob S. Carter  MD PhD; Marcela V. Maus  MD PhD

首页> 外文期刊>Neurosurgical focus >Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons

【24h】

Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons

机译：胶质母细胞瘤嵌合抗原受体T细胞免疫疗法：神经外科医生的实际见解

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The prognosis for glioblastoma (GBM) remains exceedingly poor despite state-of-the-art multimodal therapy. Immunotherapy, particularly with cytotoxic T cells, represents a promising alternative. Perhaps the most prominent T-cell technology is the chimeric antigen receptor (CAR), which in 2017 received accelerated approval from the Food and Drug Administration for the treatment of hematological malignancies. Several CARs for GBM have been recently tested in clinical trials with exciting results. The authors review these clinical data and discuss areas of ongoing research.

机译：尽管采用了最新的多模式疗法，但胶质母细胞瘤（GBM）的预后仍然非常差。免疫疗法，尤其是细胞毒性T细胞疗法，是一种有前途的替代方法。也许最杰出的T细胞技术是嵌合抗原受体（CAR），该抗体在2017年获得了美国食品和药物管理局（FDA）的加速批准，用于治疗血液系统恶性肿瘤。 GBM的几种CAR最近已经在临床试验中进行了测试，结果令人鼓舞。作者回顾了这些临床数据并讨论了正在进行的研究领域。

著录项

来源
《Neurosurgical focus》 |2018年第6期|共页
作者
Bryan D. Choi MD PhD; William T. Curry MD; Bob S. Carter MD PhD; Marcela V. Maus MD PhD;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII) [J] . Anthony K Park, Saul Priceman, Ethan Gerdts, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：胶质母细胞瘤针对表皮生长因子受体变体III（EGFRvIII）的嵌合抗原受体（CAR）T细胞免疫疗法的开发
2. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma [J] . Uslu Ugur, Schuler Gerold, Doerrie Jan, Experimental dermatology . 2016,第11期

机译：将嵌合抗原受体和常规T细胞受体结合以产生表达两个其他受体（TETAR）的T细胞，用于黑色素瘤的多点免疫治疗
3. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry? [J] . Paula Salmikangas Pharmaceutical research . 2018,第8期

机译：嵌合抗原受体T细胞（汽车T细胞）用于癌症免疫疗法的行业目标？
4. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020

机译：提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
5. The Curative Potential of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies. [D] . Koduri, Megha Pallavi. 2017

机译：嵌合抗原受体T细胞疗法对B细胞恶性肿瘤的治疗潜力。
6. Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII) [O] . Anthony K Park, Saul Priceman, Ethan Gerdts, 2015

机译：胶质母细胞瘤针对表皮生长因子受体变体III（EGFRvIII）的嵌合抗原受体（CAR）T细胞免疫疗法的开发
7. Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII) [O] . 2015

机译：胶质母细胞瘤针对表皮生长因子受体变体III（EGFRvIII）的嵌合抗原受体（CAR）T细胞免疫疗法的开发

Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons

摘要

著录项

相似文献

相关主题

期刊订阅